神経機能代替の世界市場予測（2022年～2027年）

世界の神経機能代替の市場規模は、2020年の32億800万米ドルから、2027年には72億1,700万米ドルに達し、12.28％のCAGRで成長すると予測されています。

世界的な神経障害の発症率上昇は、予測期間中に世界の神経機能代替市場の成長を促進すると予想される主要な要因の1つです。さらに、糖尿病患者の増加により、多くの人が神経損傷を負っていることも、今後数年間における神経機能代替の需要急増につながると予想されます。また、聴覚障害者数は長年にわたって大幅に増加しており、今後数年間で急増すると予測されるため、評価期間中に世界の神経機能代替市場の成長をさらに増大させると予想されます。

当レポートでは、世界の神経機能代替市場を調査しており、市場の概要、市場の促進要因や抑制要因、タイプ・技術・用途・地域別の分析、競合情勢、企業プロファイルなどを提供しています。

目次

第1章 イントロダクション

• 市場の定義
• 市場セグメンテーション

第2章 調査手法

• 調査データ
• 前提条件

第3章 エグゼクティブサマリー

• 調査のハイライト

第4章 市場力学

• 市場促進要因
• 市場抑制要因
• ポーターのファイブフォース分析
  • エンドユーザーの交渉力
  • バイヤーの交渉力
  • 新規参入業者の脅威
  • 代替品の脅威
  • 業界における競合情勢
• 業界のバリューチェーン分析

第5章 世界の神経機能代替市場分析：タイプ別

• イントロダクション
• 出力神経機能代替
• 入力神経機能代替

第6章 世界の神経機能代替市場分析：技術別

• イントロダクション
• 脳深部刺激法
• 脊髄刺激法
• 仙骨神経刺激法
• 経頭蓋磁気刺激法
• 確認されていない神経への刺激

第7章 世界の神経機能代替市場分析：用途別

• イントロダクション
• 聴覚情報処理障害
• パーキソン病
• てんかん
• 眼科疾患
• 循環器疾患
• 麻痺
• アルツハイマー病
• その他

第8章 世界の神経機能代替市場分析：地域別

• イントロダクション
• 北米
  • 米国
  • カナダ
  • メキシコ
• 南米
  • ブラジル
  • アルゼンチン
  • その他
• 欧州
  • ドイツ
  • フランス
  • 英国
  • その他
• 中東・アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • その他
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • 台湾
  • タイ
  • インドネシア
  • その他

第9章 競合環境と分析

• 主要企業と戦略分析
• 新興企業と市場の有利性
• 合併、買収、合意、およびコラボレーション
• ベンダー競争力マトリックス

第10章 企業プロファイル

• SenArs
• LivaNova PLC
• Medtronic PLC
• Sonova Holding AG
• Boston Scientific Corporation
• Cochlear Ltd
• Demant AS
• Abbott Laboratories
• NeuroPace, Inc.
• BrainGate
• NDI Medica

The global neuroprosthetics market was evaluated at US$3.208 billion in the year 2020 and is projected to grow at a CAGR of 12.28% to reach a market size of US$7.217 billion by the year 2027.

Neuroprosthetics are devices that are implanted in patients having neural damage to compensate for and restore the normal functioning of the nerves, which consequently help in partially restoring normal bodily functions. The rising incidences of neurological disorders worldwide is one of the major factors anticipated to boost the growth of the global neuroprosthetics market during the forecast period. Furthermore, the growing number of diabetes patients, leading to nerve damage in many people, is also expected to lead to a surge in demand for neuroprosthetics in the coming years. Moreover, the number of people with disabling hearing loss has been increasing substantially over the years, and its projected rapid rise in the coming years is further anticipated to augment the growth of the global neuroprosthetics market during the assessment period.

The COVID-19 pandemic had a negative impact on the global neuroprosthetics market as access to healthcare was limited for non-COVID patients during the peak of the coronavirus outbreak. The focus of the healthcare system was shifted to COVID-19 patients due to a huge number of mortalities. This led to a decrease in the diagnosis and treatment of patients with disabling hearing loss, neurological disorders, and patients with other conditions requiring the use of neuroprosthetics. This led to a decrease in the demand for neuroprosthetics during the pandemic, which resulted in a decline in the market growth in 2020.

Rising cases of neurological disorders

The number of people suffering from neurological disorders is on the rise worldwide and is one of the prominent reasons anticipated to drive the demand for neuroprosthetics during the forecast period. According to World Health Organization, the number of deaths caused by neurological disorders has increased by nearly 39% in the last 30 years. It has also been stated that an increase in the number of patients with neurological disorders is being seen over the years, while the number of cases is further projected to grow in the coming years owing to a growing elderly population, a decrease in child mortality, and rise in the survival rate and life expectancy. As per data from the PAHO, the years lived with disability (YLDs) per 100,000 population in Brazil has increased from 784.06 years in 2010 to 813.74 years in 2019. In Mexico, it increased from 721.78 years in 2010 to 737.02 years in 2019. In the United States, the deaths from neurological disorders increased from 39.29 deaths per 100,000 population in 2010 to 47.39 deaths in 2019, witnessing an increase of more than 20%. The diseases such as Alzheimer's, dementia, and Parkinson's disease are some of the neurological disorders spreading fast. For instance, as per Pan America Health Organization, Canada has witnessed a surge in the disability-adjusted life years (DALYs) per 100,000 population from 351.30 in 2010 to 415.70 in 2019, growing by more than 18%.

Growing prevalence of hearing loss

As neuroprosthetics are used in severe hearing loss, the increasing prevalence of hearing loss worldwide is a significant factor expected to augment the growth of the global neuroprosthetics market in the coming years. According to data from the WHO, the absolute number of people with hearing loss in Brazil has increased from 10 million in 2008 to 13 million in 2018. In China, the number has increased from 74 million in 2008 to 96 million in 2018, while in India, the number of people with hearing loss increased from 76.5 million in 2008 to 100 million in 2018. WHO has projected that people with disabling hearing loss will increase from 430 million in 2020 to more than 700 million by 2050. This is expected to surge the demand for neuroprosthetics significantly.

North America projected to have a major market share

Geographically, the North American region is anticipated to hold a significant market share owing to the rising cases of neurological disorders in the region, especially in the United States. Furthermore, the presence of a quality healthcare system and its accessibility to the patients makes the diagnosis and treatment stronger, which is another prominent reason for the large market size of neuroprosthetics in the region. The Asia Pacific region is anticipated to witness substantial growth due to the rising prevalence of hearing loss in the region. According to data from the WHO, the absolute number of people with disabling hearing loss in South Asia is projected to increase from 131 million in 2018 to 176 million in 2030 and further to 267 million in 2050. Furthermore, the rapidly growing cases of diabetes in the region are leading to damage to the nerves and blood vessels of a large number of patients, which is further projected to surge the demand for neuroprosthetics in the Asia Pacific region during the assessment period.

Segmentation

• By Type

Output Neural Prosthetics

Input Neural Prosthetics

• By Technique

Deep Brain Stimulation

Spinal Cord Stimulation

Sacral Nerve Stimulation

Transcranial Magnetic Stimulation

Vague Nerve Stimulation

• By Application

Auditory Processing Disorders

Parkison's Disease

Epilepsy

Ophthalmic Disease

Cardiovascular Disease

Paralysis

Alzheimer's Disease

Others

• By Geography

North America

• USA
• Canada
• Mexico

South America

• Brazil
• Argentina
• Others

Europe

• Germany
• France
• UK
• Others

Middle East and Africa

• Saudi Arabia
• UAE
• Others

Asia Pacific

• China
• India
• Japan
• South Korea
• Taiwan
• Thailand
• Indonesia
• Others

TABLE OF CONTENTS

1. Introduction

• 1.1. Market Definition
• 1.2. Market Segmentation

2. Research Methodology

• 2.1. Research Data
• 2.2. Assumptions

3. Executive Summary

• 3.1. Research Highlights

4. Market Dynamics

• 4.1. Market Drivers
• 4.2. Market Restraints
• 4.3. Porter's Five Forces Analysis
  • 4.3.1. Bargaining Power of End-Users
  • 4.3.2. Bargaining Power of Buyers
  • 4.3.3. Threat of New Entrants
  • 4.3.4. Threat of Substitutes
  • 4.3.5. Competitive Rivalry in the Industry
• 4.4. Industry Value Chain Analysis

5. Global Neuroprosthetics Market Analysis, by Type

• 5.1. Introduction
• 5.2. Output Neural Prosthetics
• 5.3. Input Neural Prosthetics

6. Global Neuroprosthetics Market Analysis, by Technique

• 6.1. Introduction
• 6.2. Deep Brain Stimulation
• 6.3. Spinal Cord Stimulation
• 6.4. Sacral Nerve Stimulation
• 6.5. Transcranial Magnetic Stimulation
• 6.6. Vague Nerve Stimulation

7. Global Neuroprosthetics Market Analysis, by Application

• 7.1. Introduction
• 7.2. Auditory Processing Disorders
• 7.3. Parkison's Disease
• 7.4. Epilepsy
• 7.5. Ophthalmic Disease
• 7.6. Cardiovascular Disease
• 7.7. Paralysis
• 7.8. Alzheimer's Disease
• 7.9. Others

8. Global Neuroprosthetics Market Analysis, by Geography

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. USA
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. Germany
  • 8.4.2. France
  • 8.4.3. UK
  • 8.4.4. Others
• 8.5. Middle East and Africa
  • 8.5.1. Saudi Arabia
  • 8.5.2. UAE
  • 8.5.3. Others
• 8.6. Asia Pacific
  • 8.6.1. China
  • 8.6.2. India
  • 8.6.3. Japan
  • 8.6.4. South Korea
  • 8.6.5. Taiwan
  • 8.6.6. Thailand
  • 8.6.7. Indonesia
  • 8.6.8. Others

9. Competitive Environment and Analysis

• 9.1. Major Players and Strategy Analysis
• 9.2. Emerging Players and Market Lucrativeness
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Vendor Competitiveness Matrix

10. Company Profiles 

• 10.1. SenArs
• 10.2. LivaNova PLC
• 10.3. Medtronic PLC
• 10.4. Sonova Holding AG
• 10.5. Boston Scientific Corporation
• 10.6. Cochlear Ltd
• 10.7. Demant AS
• 10.8. Abbott Laboratories
• 10.9. NeuroPace, Inc.
• 10.10. BrainGate
• 10.11. NDI Medica